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 Statins are effective in improving depressive symptom scores in clinically depressed 
population 
 
 Statins do not induce depressive symptoms in non-depressed populations 
 
 Statin use is associated with numerically lower depressive symptom scores in clinically 
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Background: Clinical trials of the effects of statins in people with and without depressive  
symptoms at baseline have yielded conflicting results with studies reporting both an increase and 
decrease in depressive symptoms. To address these inconsistences, a systematic review and 
meta-analysis has been conducted to determine the effects of statins on depression in those with 
or without clinical major depression.  
 
Methods: A comprehensive literature search was conducted in MEDLINE, EMBASE and 
PsychINFO to identify relevant articles that met predefined inclusion and exclusion criteria. The 
primary outcome measure was the mean difference in depression scores at endpoint between the 
statin and placebo groups which was computed using random effects model. 
 
Results: 10 articles were found and used to determine the effects of statins on depressive 
symptoms. Subgroup analyses were performed to determine the effects of statins in patients with 
and without depression at baseline. Overall, statin use was associated with significantly lower 
scores on depression rating scales compared with the placebo use (SMD -0.309, CI: -0.525, -
0.094; p= 0.005). The subgroup analysis showed significant effects in the depressed population 
(SMD: -0.796, CI: -1.107, -0.486, p= 0.001) but not in the non-depressed population (SMD: -
0.153, Cl -0.353, 0.047, p= 0.113).  
 
Limitations: There was high heterogeneity in the studies included and only two studies had low 
risk of bias. 
 
Conclusion: The results suggest that statins are effective in improving depressive symptoms, 
particularly in those with clinical depression and that they do not worsen depression in non-
depressed subjects. 
 

















Depressive disorders are common and can affect anyone and at any age. World Health 
Organization (WHO) estimates suggest that depression affects more than 300 million people of 
all ages globally (WHO | Depression, 2017). While the estimates of prevalence of major 
depressive disorder vary, a recent epidemiological study showed that the 12-month prevalence of 
DSM.5 (APA, 2013) major depressive disorder (MDD) is 10.4% and lifetime prevalence is 
20.6% (Hasin et al., 2018)  
 
Depressive disorders are commonly treated with antidepressant medications or psychological 
treatments or their combination. It is estimated that about a third of patients with MDD exhibit 
some degree of refractoriness to these treatment strategies (Rush et al., 2006); augmentation with 
atypical antipsychotics or ECT or other somatic agents are effective in improving only a 
proportion of such patients.   
 
Hence, there is a continued search for newer treatments for managing patients with refractory 
depression; one potential option based on neurobiological data is to target inflammation. This 
strategy is based on several lines of evidence that suggest a significant relationship between 
inflammation and depression: First, depression is observed more commonly in those with 
inflammatory diseases (Benros et al., 2013); Second, elevated levels of C reactive protein, 
interleukin (IL)-6, tumor necrosis factor alpha (TNF-α) and IL-1 receptor antagonist have been 
reported in people with depression compared with healthy controls (Liu., et al  2012); Third, 
there is evidence that infusions of Interferon α and cytokines induce depressive symptoms 
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depression and the trials of anti-inflammatory interventions such as nonsteroidal anti-
inflammatory agents (NSAIDs), minocycline, n-acetylcysteine, and monoclonal antibodies as 
possible treatments for depression. Indeed, a recent meta-analysis supports the notion that anti-
inflammatory agents are effective in treating depressive symptoms (Hussain et al., 2017). 
 
Statins have been considered as a potential treatment for depression due to their strong anti-
inflammatory properties  (Devaraj., et al 2007).. Statins have been reported to reduce C-reactive 
protein levels, inhibit monocyte expression of pro-inflammatory cytokines and inhibit 
lymphocytes by blocking leukocyte function antigen-1(LFA-1).These drugs are widely used in 
primary and secondary prevention of cardiovascular disease and they are in general very well 
tolerated. Several studies have examined the relationship between statin use and depression using 
various designs. A meta-analysis of observational studies reported that the likelihood of 
depression was 32% lower in statin users compared to those who were not taking statins (Parsaik 
et al., 2014).  A large Swedish cohort study of over 4.5 million people also showed that statin 
users were 5%-8% less likely to develop depression compared with those who were not taking 
statins (Redlich et al., 2014). Further, a more recent study reported that use of statins in 
association with selective serotonin re-uptake inhibitors (SSRIs) was associated with 36% lower 
risk of hospitalization for depression compared with the use of SSRIs only (Köhler et al., 2016).  
 
The effects of statins on depression have also been examined in randomized placebo controlled 
trials (RCTs) in people without clinical depression at baseline. In contrast to observational 
studies, these trials have reported conflicting findings with  some studies suggesting that statins 












   
6 
 
others reported a reduction in depressive symptoms with statin use (Ormiston et al., 2003; Sparks 
et al., 2005). Given the conflicting findings, a systematic review and meta-analysis was 
conducted in 2012 to address this controversy (O’Neil et al., 2012). This meta-analysis included 
seven randomized placebo control trials (pooled total of 2105 subjects) with participants that 
were either healthy or had documented medical conditions (history of cardiovascular disease, 
hypercholesterolemia etc.) and concluded that there were neither benefits nor adverse effects on 
the primary outcome of psychological well-being or a secondary outcome of depression. 
However, the statin use was associated with significant improvements in profile of mood states 
scores relative to placebo  (O’Neil et al., 2012) but this was based on data from only 2 of the 
studies. Since these results are only partly consistent with observational studies, the authors 
suggested that further larger clinical trials are needed to assess the effects of statins on 
depression. 
 
The efficacy of statins was also assessed in patients with clinical depression in randomized 
controlled trials (Ghanizadeh and Hedayati., 2013) (Haghighi et al., 2014). (Gougol et al., 2015).  
Statins were used as adjunctive therapy to SSRIs in these trials these trials, whose duration 
varied from 6 to 12 weeks. A systematic review and meta-analysis that included these 3 
randomized placebo controlled trials showed that statin add-on therapy to antidepressants was 
effective in improving depressive symptoms as indicated by significant reduction in  depressive 
symptoms on the Hamilton Depression rating scale score (Standardized Mean Difference: -0.73; 
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Thus, the systematic reviews published to date have suggested that statin use in those that are not 
clinically depressed may not have a beneficial effect on psychological well-being while in those 
that are clinically depressed, statin adjunctive therapy is effective. The failure to show beneficial 
effects of statins on depression in clinical trials of non-depressed population conflicts with the 
data from observational studies which showed clear benefits in reducing the incidence of 
depression.   
 
―Given these conflicting data, the objective for the current study was to conduct a 
comprehensive systematic review and meta-analysis by combining data from all relevant 
randomized double blind placebo controlled trials that evaluated the effects of statins on 
depressive symptoms in both depressed and non-depressed populations. We have also 
conducted a sub-group analysis to determine the effect of statins in those depressed at 
baseline in the trials depressed and the non-depressed study participants‖. 
 
Materials and Methods 
Search strategy 
Boolean terms “statin*”, “depress*” and “controlled trial” were used for search in MEDLINE, 
EMBASE and PsychINFO from inception to January 2, 2019 by two independent reviewers 
(MSY and KSY) to identify relevant articles. Any discrepancies were discussed and reviewed 
with the third researcher (AVR) and resolved. Both MeSh terms and keywords were used to 
cover subject heading as well as appearances in titles or abstracts in all databases. The full details 
of the search strategy can be found in supplemental figure 1. To tailor results, pre-specified 
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supplemental figure 1. These searches yielded over 400 results; to these, search limits were 
applied to exclude any obvious papers that did not answer the study question or would not be 
suitable for analysis such as those which were not full text articles or papers not in English. 
  
Inclusion and exclusion criteria 
The inclusion and exclusion criteria for the studies were as follows:  
(1) Inclusion of subjects 18 years or older 
(2) studies were randomized double blind controlled trials of a statin (or multiple statins) vs a 
placebo 
(3) studies that collected data on depressive symptoms at the end of study irrespective of whether 
they were depressed or not at study entry  
(4) studies that reported mean or medians and standard deviations for depressive symptoms on a 
rating scale at the end of the study   
(5) depressive symptoms were rated on a depression rating scale eg. Hamilton Depression rating 
scale (Hamilton, 1960), Beck Depression inventory (Beck, et al., 1961), Geriatric Depression 
scale (Yesavage, et al., 1982) etc.  
 
Any duplicate papers, or papers not in English were excluded. 
 
The full texts of the articles were reviewed in detail to assess if they met the inclusion criteria. 
Further, the bibliography of these papers was reviewed to check for any additional missing 
studies from the original search but none were found. The studies that met the inclusion and 
















Data extraction and Primary Outcome Measure 
To extract all relevant data, the standard form from the Cochrane handbook was used as a guide. 
The following key pieces of information were extracted for each study: the study design, study 
duration, sequence generation, allocation concealment, blinding, information of participants 
(diagnostic criteria, age, sex), intervention groups, primary outcomes of the paper, and results. 
For results, specifically, in order to complete the meta-analysis, the same category of data was 
extracted as described below.  
 
The primary outcome measure was the mean difference in end of trial depression scores between 
the statin and placebo groups. To compute this, the mean depression rating scale score and 
standard deviation at the end of the study for both the statin and placebo groups from each study 
were extracted. These values were compared between the statins and placebo groups to compute 
the standardized mean differences in order to estimate the effect of statins on depressive 
symptoms. If any publications did not report endpoint data, the first author of the study was 
contacted in order to obtain the data. Any papers where endpoint data was unobtainable were 
excluded from the meta-analysis.  
 
Risk of bias assessment  
The Cochrane Collaboration’s tool was used to assess risk of bias (Higgins, et al., 2011). The 
Form 8.5 a covers potential sources of bias including selection bias (random sequence 
generation, allocation concealment), performance bias (blinding of participants and personnel), 
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reporting bias (selective reporting). For each study, each category was assigned either a low risk 
(green), unclear risk (yellow) or high risk of bias (red). Attrition bias was allocated low risk if 
the dropout rate was less than 20% due to low numbers of participants in each of the studies. For 




To evaluate the data that were extracted from the trials, a meta-analysis was conducted. The 
analysis assessed all the articles included in this review. A subgroup analysis was also performed 
between two different groups of participants included in this review. The first group included 
participants with baseline depressive symptoms. In these studies, participants were diagnosed 
with major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders 
criteria and they had a Hamilton Depression rating score (HDRS) of 22 or greater. The second 
subgroup was the non-depressed population composed of “healthy” participants or those with 
other medical conditions such as multiple sclerosis or mild brain trauma etc. These studies used 
various rating scales to gauge level of depressive symptoms experienced by the participants at 
baseline and at the end of the study. For the analysis, the mean and standard deviation of 
depressive symptoms at the end of the study at the final follow up were compared. In trials that 
included more than one statin or different doses of the same statin, the data for the statin and 
dose which was most comparable to the other included trials using that statin e.g. Atorvastain 
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The meta-analysis was performed using the Comprehensive Meta-Analysis software version 2.0 
(Biostat, Englewood, NJ, USA). A random effects model was used to estimate the standardized 
mean difference in depression scores between the statin group and placebo group. The same 
model was used for subgroup analysis to assess the effects of statins in depressed and non-
depressed populations. A sensitivity analysis was conducted by removing one study at a time 
iteratively to ensure that the overall results of this meta-analysis were not driven by any one 
study. A Q statistic was computed to test for heterogeneity and an I
2
 was estimated to quantify 
the magnitude of heterogeneity. Publication bias was assessed with the funnel plot test and 
Eggers regression intercept. The classic fail safe test was also run to estimate the number of 
missing studies needed to alter the results.  
Results 
The search strategy yielded a total of 155 papers were found (85 from MEDLINE, 59 from 
EMBASE, 11 from PsychINFO) After reviewing the title and abstracts of these 155 articles, 19 
articles were found to match all the inclusion criteria.  
 
This left a total of 10 papers which were included in the meta-analysis (See PRISMA flow chart 
in Figure 1).(Harrison and Ashton, 1994; Gengo, et al., 1995; Wardle, et al., 1996; Muldoon, et 
al., 2000; Stewart, et al., 2000; Ghanizadeh and Hedayati, 2013; Haghighi, et al., 2014; Gougol, 
et al., 2015; Chan, et al., 2017; Robertson, et al., 2017). 
 
Of the 10 papers included, three of the articles were trials conducted on participants diagnosed 
with clinical depression. Seven of the articles were trials of non-depressed participants. All trials 
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study lengths varied between four weeks to four years. The trials which assessed the efficacy of 
statins in depressed patients had on average a much shorter trial duration (6-12 weeks) while the 
trials of statins in healthy subjects, and in those with medical conditions were much longer and 
some had follow-up periods up to four years in duration. The statins were used in trials of 
depressed populations as an add-on therapy to antidepressants such as citalopram or fluoxetine. 
Four different statins were used across the ten studies and these included atorvastatin, 
simvastatin, pravastatin, and lovastatin. A summary of the included papers can be seen in table 1. 
 
 
Assessment of Bias 
 
For each area of potential bias, the articles were allocated a low (green), unknown (yellow) or 
high (red) risk of bias (Supplemental figure 2). Three studies were assigned a low risk of bias 
(Haghighi, et al., 2014; Gougol, et al., 2015; Chan, et al., 2017). These papers included detailed 
descriptions of randomization, allocation concealment, and how both the participants and 
personnel were blinded. Several other studies were assigned unclear risks due to the lack of 
explanation of randomization method, blinding methods etc. Out of the 10 studies, only two did 
not have a selective reporting bias (Chan, et al., 2017; Robertson, et al., 2017).  
 
 
Effect of statins on depression 
 
The primary analysis included a total of 10 studies that had a total sample size of 2,517, of which 
1,348 received statins and 1,169 received placebo. A random effects analysis was conducted to 
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that statins were significantly more effective than placebo in reducing depressive symptoms 
(SMD= -0.309; 95% CI: -0.525, -0.094; P=0.005) (Figure 2). 
  
A subgroup analysis showed that statins were effective in the depressed population (SMD=-
0.796; 95% CI: -1.107, -0.486; p=0.0001). In the non-depressed population, statins group had 
numerically greater reduction in depressive symptoms but the difference was not significant 
statistically (SMD=-0.153; 95% CI: -0.353, 0.047; P=0.13) (Figure 3).  
 
 
The results of the iterative leave-one-study out sensitivity analysis are displayed in 
supplementary figure 3 in supplementary materials. The point estimates for standardized mean 
difference remained stable and significant indicating that no one study unduly influenced the 
overall results of this meta-analysis. 
 
The observed statistical heterogeneity as indicated by the Q value (q= 35.81; p=0.0001) was 
significant. The I
2 
which was computed to quantify the magnitude of heterogeneity was high, 
I
2
=74.86) suggesting moderate to high heterogeneity, hence a random effects model was used in 
this meta-analysis to account for the heterogeneity between the studies included. A classic fail 
safe analysis was also completed which indicated that 54 studies with null results would be 
needed in order to make the main finding of this meta-analysis insignificant. Inspection of funnel 
plot (see supplementary figure 4) showed slight asymmetry but this is to be expected given the 
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The main finding of this analysis is that statin use is associated with significantly lower 
depressive symptom scores compared with placebo. This suggests that statins are effective in 
improving depressive symptoms. This refutes the results of some clinical trials which reported 
that statins cause depressive symptoms or adverse effects on psychological well-being. Further, a 
subgroup analysis showed that statins were effective in reducing depressive symptoms in those 
with major depression. In subjects without depression, reduction in depressive symptoms was 
numerically greater in the statins group, but this difference was not significant. This suggests that 
statins at the very least do not worsen depressive symptoms in those without clinical depression. 
 
Several studies in this meta-analysis did not collect baseline depression scores as they included 
non-depressed populations. Hence, the endpoint depression scores rather than the mean change 
scores in each trial were used to estimate the mean differences between the groups. Thus, it could 
be argued that any baseline differences in the severity of depressive symptoms may have created 
a bias in the estimate of the treatment effect. However, randomization to different arms at 
baseline would have significantly reduced this bias as the treatment and control groups were 
balanced in terms of clinical characteristics. An Analysis of Covariance (ANCOVA) with 
baseline depressive symptoms scores as a covariate would have removed the effects of any 
potential differences in baseline depressive symptom scores, but these were available for patients 
















There was a statistically significant heterogeneity as indicated by significant Q statistic and high 
I
2
. However, this was to be expected, as the studies included consisted of two distinct study 
populations (depressed and non-depressed participants). Furthermore, some of the non-depressed 
participants included subjects with other medical conditions such as multiple sclerosis and mild 
traumatic brain injury. The studies also varied in terms of the ages of included participants, 
duration of trials, and were conducted in different regions of the world. Such heterogeneity is 
expected to result in differences in magnitude of benefit with treatments. Hence, a random 
effects model was used to account for such heterogeneity in calculating the standardized mean 
differences between the groups.  
 
Given the heterogeneity in the studies included, it is important to ensure that the main finding of 
the current study (i.e. that statins are more effective than placebo) is not driven by the results of 
any one study. Reassuringly, the iterative sensitivity analysis which removed one study at a time 
to assess the impact of each study on overall finding, showed that the standardized mean 
difference in favour of statins remained stable and significant, indicating that no one study 
accounted for the overall findings of this meta-analysis. 
 
The data was also evaluated for any impact of publication bias, and found such was unlikely. 
Although the funnel plot showed slight asymmetry, the results of Eggers regression (intercept= -
1.786; 95% CI -4.08, 0.50, p= 0.11), indicated a low risk of publication bias. Furthermore, the 
classic fail safe test showed that 54 missing studies with an effect size equal to zero would be 
















The finding that statins are effective in improving depressive symptoms is consistent with the 
results of a meta-analysis of observational studies which indicated lower incidence of depression 
in statin users compared with general population that are not taking statins (Parsaik, et al., 2014). 
These results are also consistent with that of a large cohort study which indicated a 5%-8% lower 
risk of depression in those using statins compared with those not taking statins (Redlich, et al., 
2014).  
 
The findings of the current investigation are consistent with that of a previous meta-analysis 
which examined the effect of statins on depressive symptoms in patients with clinical depression 
(Salagre, et al., 2016). That analysis included a total of 165 patients (statins n=82; placebo n=83) 
from three randomized double blind placebo controlled trials of between 6 weeks to 12 weeks in 
duration. Their data suggested a standardized mean difference of -0.73 (CI: -1.05, -0.41) in 
favour of statins suggesting that statins are significantly more effective than placebo in 
improving depressive symptoms when used as an adjuvant therapy to antidepressants in persons 
with moderate to severe depression. While the overall findings are consistent, the magnitude of 
effect size for statins was lower (SMD: -0.309, CI: -0.525, -0.094) in the current meta-analysis.  
This is likely to be because this meta-analysis included data from studies of both depressed and 
non-depressed populations. Indeed, a sub-analysis assessing the effect of statins in the depressed 
subgroup showed a SMD of -0.796 (CI: -1.107, -0.486) which is similar to the magnitude of 
benefit observed with statins in the previous report (Salagre, et al., 2016). Thus, these results 
clearly confirm the findings of the previous meta-analysis which suggested that statin adjunctive 
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depression. One important caveat with the statin trials in depressed population is that all three 
published trials to date were conducted in one country. Although a study conducted in Korea 
which assessed the effects of statins given in conjunction with antidepressants on depression in 
patients with acute coronary syndrome suggested that more patients improved in the statin and 
antidepressant group compared with the no medication group, this study did not randomize 
subjects to statins or no medication (Kim, et al., 2015). Thus, although the study results of Kim 
and colleagues is supportive, it cannot be taken as a confirmatory evidence. Therefore, it may be 
prudent to wait for replication of these findings in depressed populations from other countries 
before firm conclusions are drawn.  
 
Although the main finding of current meta-analysis suggests that statins are effective in 
improving depression, a subgroup analysis did not demonstrate significant benefit of statins in 
non-depressed populations. This latter finding is consistent with a previous meta-analysis which 
examined the impact of statins on psychological well-being in healthy subjects and in those with 
other medical conditions such as history of cardiovascular disease, Alzheimer’s disease etc. 
(O’Neil, et al., 2012). That meta-analysis included seven randomized controlled trials with a 
pooled sample of 2,105 participants (statins n= 1,133; placebo n= 972). A test for overall effect 
showed that the standardized mean difference between the two groups was -0.08 (95% CI: -0.29, 
0.12) which was not significant. Based on this, O’Neil and colleagues concluded that statins had 
neither a positive nor adverse effect on overall psychological well-being. However, it must be 
remembered that although statins were not significantly more effective than placebo in 
improving depression in non-depressed subjects, statin use was associated with numerically 
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the question as to whether a lack of significant benefit in the non-depressed population might be 
due to a “floor effect”; that is if these patients had very few if any depressive symptoms to begin 
with, there is not that much room for significant improvement in symptoms. Further, unlike the 
studies of depressed populations all of which used standard rating scales for depression, the 
studies in non-depressed populations used a variety of scales to measure mood symptoms which 
may have impacted the results. Indeed, a separate analysis conducted by O’Neill and colleagues 
of those studies that reported specifically mood outcomes using profile of mood states scale 
showed that statins were associated with significant improvements in mood scores (O’Neil, et 
al., 2012). However, this latter analysis was based on the results of only two studies and hence 
caution is needed in interpreting these findings. Overall though, while there is no firm evidence 
yet that statins improve depressive symptoms in non-depressed populations, the evidence is 
sufficiently strong to indicate that at the very least, statins do not induce depressive symptoms or 
have adverse effects on psychological well-being.  
 
Although the exact mechanisms by which statins might improve depressive symptoms is 
unknown, the leading theory is that statins decrease the inflammation and oxidative stress 
reported to be commonly associated with depression. As previously stated,  patients with clinical  
depression have elevated levels of C reactive protein, interleukin (IL)-6, tumor necrosis factor 
alpha (TNF-α) and IL-1 receptor antagonist  (Liu, et al., 2012). Further, a meta-analysis of 23 
studies with close to 5000 subjects showed that depression is associated with increased levels of 
oxidative stress markers (Palta, et al., 2014).  As statins have both anti-inflammatory and 
antioxidant properties, these could be the main mechanisms of action for their effectiveness in 
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some differences in chemical properties between statins and these may have a potential impact 
on their efficacy in treating depression. For instance, some statins are more lipophilic than others 
and these differences affect their ability to cross blood-brain barrier. Lovastatin and simvastatin 
cross the blood brain barrier more easily in comparison to pravastatin and atorvastatin. A head to 
head statin comparison trial of atorvastatin and simvastatin on decreasing depressive symptoms 
showed that in those who were allocated to the simvastatin group showed greater improvements 
in Hamilton Depression rating scale scores in comparison to the atorvastatin group (Abbasi et al., 
2015). Further, the simvastatin group had a faster response to treatment showing improvements 
earlier than the atorvastatin group (Abbasi et al., 2015).  If it is true that the reasons statins have 
an effect on depressed people is due to inflammation found in the brain it could mean that using 
a statin which can easily cross the BBB and work directly on the brain has a more powerful 
antidepressant effect.  
It has also been suggested that  the efficacy of statins in improving  depressive symptoms might 
be secondary to improvements in quality of life observed in those taking statins which result in  
decreased incidence of cardiovascular events (Yang, et al., 2003).  Depression is a significant 
risk factor in those with cardiovascular disease. By decreasing the chances of developing a 
cardiovascular disease with statin treatment, the patient’s quality of life can improve and 
symptoms of depression can be reduced. It can be assumed that those who have cardiovascular 
diseases are likely to be less healthy, and are more susceptible to developing depression due to 
these health issues and other comorbidities. Therefore, using a statin to treat and or prevent 
cardiovascular events from reoccurring can lead to an increased quality of life and decreased 
likelihood of developing depression. Usually the lipid lowering effect produced by statins is 












   
20 
 
incidences to be seen. Those who take prolonged statin therapy are more likely to be more health 
conscious leading to better adherence to medications.  
Another possibility is that inflammation and oxidative stress predispose individuals to both 
cardiovascular disease (Arévalo-Lorido, 2016) and depression. Therefore, statins by reducing 
inflammation and oxidative stress may help reduce the likelihood of cardiovascular events and 
depression. Lastly, it has also been suggested that statins improve brain perfusion and 
oxygenation (Glueck, et al., 1993) and thus improve depression. Whatever the mechanism might 
be, the results of the current meta-analysis provide optimism for further investigating the efficacy 
of statins in larger trials to confirm these findings. 
 
Limitations 
This systematic review and meta-analyses has some limitations. Many studies included in this 
meta-analysis were allocated an unknown risk of bias based on the Cochrane tool. This 
determination was usually due to a lack of explanation of key study design issues in methods in 
several studies. The trials utilized different rating scales and questionnaires to assess the outcome 
measure of interest (i.e. depressive symptoms experienced by the participants). Some used the 
Hamilton Depression rating scale, while others used the CES-D. One paper even used a variation 
of a General Health questionnaire. Due to the variations in scales, it is hard to compare them to 
each other as they are all scored in different ways. Some of the scales used were self-
administered and some were administered by a health care professional. This can cause 
variations in results obtained. With a self-administered scale, a participant could have for 
example misinterpreted a question, on the other hand with a scale administered by a health care 












   
21 
 
The comprehensive meta-analysis software used did not take into account the risk of bias of each 
study. In this regard, the Cochrane collaborators RevMan-5 software might have been better as 
that program takes into account the risk of bias as well as the sample size and weights for each 
study in the analysis accordingly. However, to address heterogeneity, a random effects model 
was used in this meta-analysis which is a more conservative means to estimate the standardized 
mean difference between the groups.  
 
Conclusion 
The findings of this systematic review provide preliminary evidence that statins are an effective 
adjunctive treatment in those who are clinically depressed. In those who are not depressed, the 
use of statins does not appear to be associated with any significant benefit in improving 
depression. This, however, may be because these patients have limited depressive symptoms and 
thus not much room for improvement. Importantly, the evidence suggests that statin use in such 
populations is not associated with induction or worsening of depressive symptoms. Therefore, 
the current meta-analysis clearly refutes the findings of some trials which stated that statins 
induce depressive symptoms in non-depressed populations. While the results of the current meta-
analysis are very promising and supportive of benefits of statin therapy, further research and 
trials with larger sample sizes need to be conducted in order to fully explore the benefits of 
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 Study population  Study design Follow up date(s) Depression rating scale 
used 
Chan et al., 2017 Patients aged 18-65 years meeting 
McDonald diagnostic criteria for 
Multiple sclerosis  
Double blind, parallel 
group randomised 
placebo controlled trial 
6, 12, 18, and 24 
months 
Hamilton Depression 
Rating Scale  
Gengo et al., 1995 Patients aged 40-60 years with 
primary moderate 
hypercholesterolemia  
Double blind placebo 
controlled two period 
incomplete block 
crossover study 
Day 29  Profile of mood states: 
the monopolar form of 
this commercially 
available test was used. 
Ghanizadeh and 
Hadayati, 2013 
Patients diagnosed with MDD per 
Diagnostic and Statistical Manual 






Week 6 Hamilton Depression 
Rating Scale  
Gougal et al., 2015 Patients aged 20-70 who have a 
MDD based upon Diagnostic and 
Statistical Manual of Mental 
Disorders (fourth edition), with a 
HDRS of 22 or higher 
Parallel-group, double 
blind, placebo 
controlled clinical trial  
 
Week 6 Hamilton Depression 
Rating Scale  
Haghigil et al., 2014 Patients with a current unipolar 
depressive disorder per the 
Diagnostic and Statistical Manual 
of Mental Disorder, Hamilton 






Week 12 Hamilton Depression 
Rating Scale  
Harrison and Ashton, 
1994 
Healthy patients aged 20-32 Double-blind, placebo-
controlled, randomised 
crossover study 
Week 4 Hospital Anxiety and 
Depression Rating Scale 
Muldoon et al., 2000 Generally healthy patients aged 




controlled trial   
6 Months  Hamilton Depression 
Rating Scale  
Robertson et al., 2017 Patients aged 18-50 with injury 
occurring with the preceding 24 
our and no hospitalization for the 
injury for which the participant 
enrolled.  
Randomized placebo 
controlled trial  
Day 7, 1 and 3 
months 





Stewart et al., 2000 Patients aged 31-74 years with 
fasting serum cholesterol level of 
4.0-7.0 mmol/L, and have a 
history of acute myocardial 
infarction, or hospitalization for 
unstable angina in the previous 3-
36 months  
Randomized double 
placebo trial  
 
6 months, 1,2,3 and 4 
Years  
30- question version of 
the General Health 
Questionnaire (GHQ)  
Wardle et al., 1996 Patients aged 40-75 years with 
blood total cholesterol 
concentration of 3.5mmol/l or 
greater and are considered to be at 
a higher risk of coronary heart 
disease, angina pectoris, stroke, 
transient ischemic attack, 
peripheral vascular disease, treated 
diabetes mellitus, or hypertension)  
Randomized placebo 
controlled trial  
Week 152 Shortened version of the 
profile of mood state 
questionnaire  

















 Intervention Treatment  Patients 
allocated to each 
treatment  
Mean score at 
endpoint 
Chan et al., 2017 Simvastatin 80 mg or 








Gengo et al., 
1995 
Lovastatin 40mg or 
Placebo taken with 










Lovastatin 30mg or 
Placebo once daily 
with fluoxetine up to 







Gougol et al., 
2015 
Simvastatin 20mg or 
Placebo once daily 
with Fluoxetine 
20mg once daily for 
the first 2 weeks then 







Haghigil et al., 
2014 
Atorvastatin 20mg or 









Simvastatin 40mg or 







Muldoon et al., 
2000 
Lovastatin 20mg or 







Robertson et al., 
2017 
Atorvastatin 1mg/kg 
(up to 80 mg) or 







Stewart et al., 
2000 
Pravastatin sodium 
40mg or Placebo 








Wardle et al., 
1996 
Simvastatin 20mg or 






9.5 (3.5)  
